- Home
- RCKT vs TNGX Comparison
RCKT vs TNGX Comparison
Compare RCKT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- TNGX
- Stock Information
- Founded
- RCKT 1999
- TNGX 2014
- Country
- RCKT United States
- TNGX United States
- Employees
- RCKT N/A
- TNGX N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- TNGX Health Care
- Exchange
- RCKT Nasdaq
- TNGX Nasdaq
- Market Cap
- RCKT 328.6M
- TNGX 351.2M
- IPO Year
- RCKT N/A
- TNGX N/A
- Fundamental
- Price
- RCKT $3.14
- TNGX $6.82
- Analyst Decision
- RCKT Buy
- TNGX Strong Buy
- Analyst Count
- RCKT 13
- TNGX 5
- Target Price
- RCKT $14.79
- TNGX $10.50
- AVG Volume (30 Days)
- RCKT 3.6M
- TNGX 2.0M
- Earning Date
- RCKT 08-08-2025
- TNGX 08-05-2025
- Dividend Yield
- RCKT N/A
- TNGX N/A
- EPS Growth
- RCKT N/A
- TNGX N/A
- EPS
- RCKT N/A
- TNGX N/A
- Revenue
- RCKT N/A
- TNGX $40,990,000.00
- Revenue This Year
- RCKT N/A
- TNGX N/A
- Revenue Next Year
- RCKT $608.87
- TNGX N/A
- P/E Ratio
- RCKT N/A
- TNGX N/A
- Revenue Growth
- RCKT N/A
- TNGX 10.09
- 52 Week Low
- RCKT $2.19
- TNGX $1.03
- 52 Week High
- RCKT $26.98
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- RCKT 49.02
- TNGX 71.71
- Support Level
- RCKT $3.03
- TNGX $6.36
- Resistance Level
- RCKT $3.54
- TNGX $7.20
- Average True Range (ATR)
- RCKT 0.21
- TNGX 0.47
- MACD
- RCKT 0.09
- TNGX -0.03
- Stochastic Oscillator
- RCKT 49.37
- TNGX 77.91
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.